PDCD1 and neoplasm: Interestingly, the combination of anti-CTLA-4 with RMC-4998 and RMC-4550 displayed a similar effect to the triple combination with anti-PD-1 (Supplementary Fig. 4d), whereas the quadruple combination of targeted and ICB therapies led to tumour eradication in almost all mice (Fig. 4c, e and Supplementary Fig. 4d).